Compare Humana Inc (HUM) vs iShares MSCI China ETF (MCHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs iShares MSCI China ETF — how do they compare? Humana Inc trades at $444.98 (market cap $47.61B), while iShares MSCI China ETF trades at $52.8 (market cap $6.00B). The key difference: Humana Inc is far larger — about 7.9× iShares MSCI China ETF's market cap, and Humana Inc pays a 0.89% dividend while iShares MSCI China ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and iShares MSCI China ETF for 63 Days on average.
| HUM | MCHI | |
|---|---|---|
Market Cap | $47.61B | $6.00B |
Volume | 1,827,332 | 1,917,899 |
Sector | Health | Broad Market / Factor |
52-Week High | $409.85 | $65.59 |
52-Week Low | $163.67 | $50.48 |
Typical Hold Time | 53 Days | 63 Days |
Enterprise Value | $54.97B | — |
Dividend Yield | 0.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $387.12, down 4.24% today, but maintains a bullish technical outlook with strong institutional support. The stock shows mixed fundamentals with revenue growth to $129.66B in 2025 but declining profit margins at 0.88%. Recent analyst upgrades, including Barclays' $515 target on September 25, 2026, highlight optimism despite ongoing Medicare Advantage plan adjustments affecting member transitions.
Investment outlook remains cautiously optimistic with a consensus price target of $432.63 offering 12% upside. Risks include margin compression, regulatory scrutiny from Medicare billing practices, and competitive pressures in managed care. The company's strong cash position of $20.44B and consistent dividend payments provide stability amid enrollment volatility.
MCHI trades at $51.64, down 1.11% with a bearish technical signal from moving averages and oscillators. The ETF faces headwinds from China's economic challenges including industrial overcapacity and trade tensions, though corporate profits surged 26% in Q2 2026. Support levels cluster around $51-52 with resistance at $52, indicating consolidation near current levels amid mixed market sentiment.
The outlook remains cautious due to China's macroeconomic pressures and global trade friction, though historical discount to US indices presents potential value. Key risks include export restrictions, protectionism threats, and domestic consumption weakness. Institutional activity shows mixed positioning with recent acquisitions offset by reductions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →
